Indacaterol

證據等級: L5

預測適應症: 10 個

Indacaterol: From Respiratory Bronchodilation to Nephrogenic Syndrome of Inappropriate Antidiuresis

One-Sentence Summary

Indacaterol is a long-acting β2-adrenergic receptor agonist (LABA) bronchodilator used in respiratory disease (COPD/asthma), most commonly as part of fixed-dose combinations with glycopyrronium and/or mometasone. The TxGNN model's top-ranked prediction for this candidate pack is Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD), but this ranks among the pack's ten predictions with zero clinical trials and zero publications supporting it, and the accompanying mechanistic review explicitly finds no plausible biological link.

Quick Overview

Item	Content
Original Indication	Not formally on record (see note below); evidence pack confirms indacaterol acts as a LABA bronchodilator for respiratory disease
Predicted New Indication	Nephrogenic Syndrome of Inappropriate Antidiuresis
TxGNN Prediction Score	99.54%
Evidence Level	L5
Finland Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Note: taiwan_regulatory.licenses is empty (drug not marketed in Finland), so no formal approved-indication text is available from that source.

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap DG002). Based on information within this evidence pack, indacaterol is a long-acting β2-adrenergic receptor agonist that activates β2 receptors on bronchial smooth muscle, raising intracellular cAMP and producing bronchodilation — the established mechanism underlying its core respiratory use (see the "bronchial disease" candidate below, which is strongly evidence-backed but represents an already-known use rather than a novel repurposing signal).

For the top-ranked candidate — Nephrogenic Syndrome of Inappropriate Antidiuresis — the evidence pack's own mechanistic review finds no plausible link: NSIAD results from activating mutations of the renal V2 vasopressin receptor, and its standard management (fluid restriction or vaptans/V2-receptor antagonists) operates through a pathway with no known interaction with β2-adrenergic signaling. The high TxGNN score therefore appears to reflect a graph-embedding similarity rather than a biologically grounded hypothesis, and no clinical trials, ICTRP records, or PubMed literature exist to corroborate it (query log entries #5–#7, all zero results).

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Finland Market Information

Indacaterol is not currently marketed in Finland — 0 authorizations are on record (taiwan_regulatory.market_status: 未上市 / Not Marketed).

Safety Considerations

Please refer to the package insert for safety information. (TFDA package insert warnings/contraindications are flagged as a Blocking data gap — DG001 — pending retrieval and parsing before any S1 safety review can proceed.)

Other Predicted Indications in This Evidence Pack

This candidate pack (TW-DB05039-multi) contains 10 TxGNN predictions for indacaterol. For context, they are summarized below; only rank 7 currently has meaningful supporting evidence, and it reflects an already-established use (respiratory bronchodilation) rather than a new repurposing opportunity.

Rank	Predicted Indication	TxGNN Score	Evidence Level	Recommendation
1	Nephrogenic syndrome of inappropriate antidiuresis	99.54%	L5	Hold
2	Headache disorder	99.53%	L5	Hold
3	Trigeminal autonomic cephalalgia	99.33%	L5	Hold
4	Paratenonitis	99.26%	L5	Hold
5	Calcific tendinitis	99.25%	L5	Hold
6	Hypertrichosis (disease)	99.23%	L5	Hold
7	Bronchial disease	99.18%	L1	Proceed with Guardrails (known indication, not novel)
8	Myositis	99.12%	L5	Hold
9	Anaphylaxis	99.07%	L4	Hold
10	Ambras type hypertrichosis universalis congenita	99.06%	L5	Hold

Conclusion and Next Steps

Decision: Hold

Rationale: Although the TxGNN score for NSIAD is high (99.54%), it is unsupported by any clinical trial or literature evidence, and the mechanistic review within this evidence pack explicitly finds no biological rationale connecting β2-adrenergic bronchodilation to a V2-receptor-mediated water-balance disorder. This is an L5 candidate (model prediction only) with a Hold recommendation from the scoring stage itself.

To proceed, the following is needed:

TFDA/Finnish package insert warnings and contraindications (Blocking gap DG001) before any safety evaluation is possible
Confirmed mechanism of action data (High-priority gap DG002)
Preclinical or mechanistic studies specifically testing β2-agonism in NSIAD or related water-balance disorders, since none currently exist
If pursuing a repurposing candidate from this pack, consider prioritizing better-evidenced signals (e.g., rank 9, anaphylaxis, L4) over the current top-ranked but mechanistically unsupported prediction
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.